fbpx

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma Chemotherapy- RVd Triplet “Impressive Response”

Share Button

“For the first time ever, a three-drug regimen resulted in a 100% response rate and a favorable tolerability profile in patients with multiple myeloma”

The good news is that, according to the article below, all newly diagnosed Multiple Myeloma (MM) patients will achieve some form of remission from their MM by undergoing a MM chemotherapy regimen RVd (revlimid, velcade, dexamethasone).

The bad news is that, according to the American Cancer Society, the survival of newly diagnosed MMers, depending on stage at diagnosis, is 4-7 years. 

Image result for image of triplet chemotherapy regimen

There is no question that a diagnosis of multiple myeloma is more hopeful today than it was 20 years ago. There is a long and growing list of both FDA approved chemotherapy regimens as well as evidence-based non-conventional therapies for MM treatment.

According to the study linked and excerpted below, about a third of MMers who undergo RVd develop chemo-induced peripheral neuropathy (CIPN). 40% of the patients studied in the research required dose reductions due to side-effects.

Newly diagnosed MMers have got to ask themselves if they can achieve a deeper, longer remission while reducing the risk of side effects. And the answer is yes.

By combining conventional chemotherapy cocktails with evidence-based, non-toxic, anti-MM nutrition, supplementation, bone health, lifestyle and mind-body therapies based on the six pathways linked below.

  1. Warburg Effect- https://en.wikipedia.org/wiki/Warburg_effect
  2.  Chronic Inflammation- https://en.wikipedia.org/wiki/Inflammation#Cancer
  3. Angiogenesis- https://en.wikipedia.org/wiki/Angiogenesis
  4. Nutrigenomics- https://en.wikipedia.org/wiki/Nutrigenomics
  5.  NF-kB (nuclear factor kappa light chain enhancer of activated B cells)   https://en.wikipedia.org/wiki/NF-κB#Clinical_significance
  6. Metrononic Therapy- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669231/

I am both a long-term MM survivor and MM cancer coach. Years of experience and research have taught me that MMer must employ the best of both conventional and non-conventional therapies in order to achieve the deepest, longest remissions with the least amount of collateral damage.

Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Impressive response rate seen with three-drug regimen for multiple myeloma

“For the first time ever, a three-drug regimen resulted in a 100% response rate and a favorable tolerability profile in patients with multiple myeloma, according to new findings…The combination of lenalidomide (Revlimid, Celgene), bortezomib (Velcade, Millennium Pharm) and dexamethasone proved highly effective for previously untreated multiple myeloma…

The rate of partial response was 100% in both the phase 2 population and overall, with 74% and 67% each achieving very good partial response or better. Complete or near-complete response was seen in 54% of patients treated at the phase 2 dosing

Nevertheless, there were still significant issues [with RVD]. The combination is complicated by painful sensory neuropathy in 32% of patients; 40% of patients required dose reductions, missed doses, or had to discontinue therapy due to toxicity…”

All proceeds benefit PeopleBeatingCancer.org, a registered 501(c)3 non-profit, and are used to further its mission to empower cancer survivors and caregivers to live longer, healthier lives.


“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”

A search of the Pubmed database for the word curcumin yields 601 studies spanning health topics from multiple myeloma (MM) and colorectal cancer, to chemotherapy regimens that integrate with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive and effective.

I have read posts about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.

The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.

The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.

I consult the independent evaluation service Consumerlab.com frequently. For one low annual payment, I can read about and evaluate all of the nutritional supplements that I take.

Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.

The challenge for every myeloma patient is to achieve the deepest, longest remission possible while sustaining the least amount of collateral damage (side effects) possible. Numerous studies document the anti-MM and integrative efficacy of curcumin.

This link is to the Google search page for “curcumin in myeloma.” Whether it is an article authored by Pat Killingsworth or Margaret from Margaret’s Corner, or PubMed, curcumin is documented to be both cytotoxic to myeloma in addition to being “integrative”  or enhancing the action of Velcade, Revlimid, and Thalidomide.

A common question asked by multiple myeloma patients considering supplementing with curcumin is about the daily dose. Unfortunately, I have several possible answers:

  • The research into MM and curcumin usually refers to a “time and dose dependent manner.” Meaning, the more curcumin the patient takes, the more MM cells are killed.
  • I read about patients with active MM taking doses at many different amounts, from 1 gram a day up to 8 grams a day.
  • For comparison, I take 400 milligrams. My MM is not active therefore I take a maintenance dose. To clarify, 1000 milligrams = 1 gram.

Recommended Reading:


Curcumin

CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.[1]

Turmeric curcumin benefits

“Are you looking for a way to boost every facet of your health with a single spice? It sounds crazy, but turmeric curcumin with BioPerine may be the magic supplement we’ve been seeking. Turmeric benefits the body and mind in more ways than you can imagine. Similar to bone broth, turmeric impacts almost every facet of life. Over 10,000 peer-reviewed and clinical studies support using turmeric for better health…”

Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers.

“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.

The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.

Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.

Based on the published reports,

exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”

According to Consumerlab.com:

“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”

To confuse things even more, many brands of curcumin are more bioavailable than others. Bioavailability means absorption in the blood stream. Bioprene is known to enhance the bioavailability of curcumin.


Recommended Reading:


CU enhances the cytotoxic and chemo-sensitizing effects of lenalidomide in human multiple myeloma cells

Background: CU, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model…

Conclusion: CU exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent.

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.

“Multiple myeloma (MM), a plasma cell malignancy, remains incurable despite the development of new therapies. CU anti-tumor effects were previously characterized in multiple myeloma, however only few MM cell lines were included in these studies.

Since myeloma is a heterogeneous disease it is important to address the impact of myeloma molecular heterogeneity in CU cell death induction.

In the present study, a large panel of human myeloma cell lines (HMCLs) (n = 29), representing the main molecular MM subgroups, was screened for CU sensitivity. We observed that CU cell death induction was heterogeneous, of note 16 HMCLs were highly sensitive to CU (LD50 < 20.5 μM), 6 HMCLs exhibited intermediate LD50 values (20.5 μM ≤ LD50 < 32.2 μM) and only 7 HMCLs were weakly sensitive (35 < LD50 < 56 μM).

Cell lines harboring the t(11;14) translocation were less sensitive (median LD50 32.9 μM) than non-t(11;14) (median LD50 17.9 μM), which included poor prognosis t(4;14) and t(14;16) cells.

Interestingly, CU sensitivity was not dependent on TP53 status. For the first time we showed that primary myeloma cells were also sensitive, even those displaying del(17p), another poor prognosis factor. We also unravel the contribution of anti-apoptotic Bcl-2 family molecules in CU response.

We found that down-regulation of Mcl-1, an essential MM survival factor, was associated with CU-induced cell death and its knockdown sensitized myeloma cells to CU, highlighting Mcl-1 as an important target for CU-induced apoptosis. Altogether, these results support clinical trials including CU in association with standard therapy.”

 

 

 

 

 

Leave a Comment:

3 comments
Add Your Reply